- #59 Politik & Verwaltung
- #59beste Platzierung
- wöchentlichErscheinungsrhythmus
- 37 mintypische Länge
- vor 4 Tagenletzte Folge
Folgenzu den neuesten
#342 Can Antitrust Be More Innovation-Centric? An Economic Conversation With Professor Richard Gilbert
Innovation is central to long-term economic welfare and deserves greater emphasis in antitrust policy. But can U.S. antitrust law be reshaped to be more innovation-centric? Professor Richard Gilbert joins hosts Anora Wang and Panos Dimitrel
#341 How Should Killer Acquisitions Be Assessed? A Discussion With Professor Nicolas Petit
Merger control regulators in the EU and around the world continue to focus on killer acquisitions. But is this concern justified in the digital sector? Professor Nicolas Petit, a leading competition law academic, joins Matthew Hall and Blai
#340 How Do You Win (and Not Lose) a Merger Trial?
Merger litigation is fast, high-stakes, and often unpredictable. So what does it take to win—or avoid losing—when the government challenges a deal? In this episode, Puja Patel and James Hunsberger are joined by Kieran Gostin, a partner at W
#339 How Do Presidents Shape Antitrust? The Oval Office and the Enforcement Pendulum
Antitrust enforcement can change dramatically between Presidential administrations. What makes the political winds flip between more and less enforcement? In this episode, former Deputy Assistant Attorney General Michael Kades joins hosts A
#338 How Clean Are Your Claims? Understanding the New Anti-Greenwashing Amendments to Canada’s Competition Act
Among the recent amendments to Canada's Competition Act are new provisions targeting so-called “greenwashing,” i.e., misleading claims in advertising regarding the environmental benefits of a product. In a related development, the Competiti
#337 What Are the Risks of a Minority Shareholding? The European Commission’s Decision in Delivery Hero/Glovo
In June 2025, the European Commission announced a decision under which it fined two competing online food delivery companies a combined total of €329 million for cartel behaviour that took place while one company held a minority stake in th
#336 What Are the Risks of Serial Acquisitions? Empirical Evidence From the Dialysis Industry
There is a growing interest in understanding the economics of serial acquisitions, particularly in the healthcare industries and markets, and whether such corporate strategies lead to changes in prices and quality causing antitrust concerns
#335 Are You Ready To Respond? Developments in Competition Law Dawn Raids
The "dawn raid" is one of the rare moments of high drama in the work of many competition lawyers. How can you be prepared when that early-morning phone call or text from a client comes? Ashley Latham, an antitrust and government investigati
#334 What’s the Word on Wage-Fixing? Cracking Down on Collusion Among Employers
The U.S. Department of Justice has made it clear that some agreements among competing employers regarding workers’ salaries or other terms of compensation--so-called “wage-fixing agreements”--may be subject to criminal prosecution. What kin
#333 Is Antitrust Fashionable This Season? Antitrust in the Fashion Industry
What happens when antitrust law meets high fashion? In this episode, experienced fashion and luxury industry counsel Andowah Newton, joins Jeny Maier and Puja Patel to unpack recent antitrust cases in the luxury and fashion industries. From
#332 What Is the Role of Behavioural Economics in Consumer Protection Enforcement? The UK’s New DMCC Act Regime
The UK's consumer protection regime changed early in 2025. How will behavioural economics be used by the UK Competition and Markets Authority (CMA) in applying the rules? Stefan Hunt, partner at Keystone Strategy in London, joins Matthew Re
#331 Wait, We Have to Tell Who? What You Need to Know About State Premerger Notifications
State legislatures around United States have passed or are on track to pass legislation that requires parties to submit notice to the state attorney general or other state authority when certain transactions result in a material change in o
#330 What's Happening in Paraguay and Costa Rica? Catching Up With International Enforcers at the 2025 Spring Meeting
While on site at the 2025 Spring Meeting of the ABA Antitrust Law Section, the Our Curious Amalgam team recorded interviews with senior competition agency enforcers from all over the world, including Paraguay and Costa Rica. In the first se
#329 What's Happening in Hong Kong, the Philippines, and Japan? Catching Up With International Enforcers at the 2025 Spring Meeting
While on site at the 2025 Spring Meeting of the ABA Antitrust Law Section, the Our Curious Amalgam team recorded interviews with senior competition agency enforcers from all over the world. In the first segment of this episode, Anora Wang s
#328 What Should I Know About Nigeria, South Africa, Egypt and COMESA? Developments in Key African Regimes
Merger control and antitrust enforcement continues to develop rapidly in Africa. What is happening in the key jurisdictions of Egypt, South Africa, Nigeria and COMESA? John Oxenham, lawyer at Primerio, and Nicolas Bremer, lawyer at Bremer,
#327 What's Happening in Germany and Portugal? Catching Up With International Enforcers at the 2025 Spring Meeting
While on site at the 2025 Spring Meeting of the ABA Antitrust Law Section, the Our Curious Amalgam team recorded interviews with senior competition agency enforcers from all over the world, including Germany and Portugal. In the first segme
#326 What's Happening in Italy and Greece? Catching Up With International Enforcers at the 2025 Spring Meeting
While on site at the 2025 Spring Meeting of the ABA Antitrust Law Section, the Our Curious Amalgam team recorded interviews with senior competition agency enforcers from all over the world, including Italy and Greece. In the first segment o
#325 What’s Your POV? A Conversation With Former Italian Prime Minister Mario Monti at the 2025 Spring Meeting
While on site at the Antitrust Law Section's 2025 Spring Meeting in Washington, D.C., Section Chair-Elect Renata Hesse interviewed Mario Monti, former prime minister of Italy (2011-2013), and European commissioner for competition (1999-2004
#324 Is Green the New Black? Greenwashing and Consumer Protection in the Fashion Industry
Sustainability claims are everywhere in the fashion industry — but how can consumers tell what’s real and what’s greenwashing? Baker McKenzie attorneys David Baay and Katia Boneva-Desmicht join Jeny Maier and Puja Patel to discuss civil lit
#323 What’s Happening in the EU? A Conversation With DG COMP Director-General Olivier Guersent at the 2025 Antitrust Spring Meeting
The 2025 Spring Meeting of the ABA Antitrust Law Section offered the Our Curious Amalgam team a chance to speak with competition law enforcers from around the world. In this episode, host Matthew Hall asks Olivier Guersent, Director-General
#322 Prices on Your Mind? Using Economics To Understand Inflation, Tariffs, and Junk Fees
We are seeing some swirling changes to the marketplace and international trade that affect prices of goods and services in our daily lives. How can economics help us cope and understand underlying concepts such as cost pass-through? Anne Ca
#321 What Is Happening at the UK CMA? Impact of the Government’s New Approach
The UK government elected in 2024 has a "growth" agenda and is pushing regulators including the UK Competition and Markets Authority to support this. What does the approach mean for the CMA? Veronica Roberts, lawyer at Herbert Smith Freehil
#320 What Can In-House Counsel Do To Tame the Premerger Notification Beast? Practical Suggestions for Complying With the New HSR Rules
New disclosure requirements for U.S. premerger notifications under the Hart-Scott-Rodino Act were announced in the fall of 2024 and became effective in February 2025. What are the practical implications of the new requirements for in-house
#319 Can We Define Overlapping Markets? Understanding the Legal and Economic Arguments
Market definition plays a central role in antitrust analysis. Is it appropriate for the U.S. antitrust agencies to identify "overlapping markets" and "submarkets" as relevant markets for antitrust purposes? Keith Klovers, Counsel at Latham
#318 How Hot Is Cartel Enforcement Around the Globe? Checking the Forecast for 2025 and Beyond
Cartel enforcement remains a priority for agencies around the world, but in recent years enforcers have continued to focus on domestic cases. With political and personnel changes in the U.S. and across the globe, what can we expect in 2025
#317 Is Artificial Intelligence Putting Data Privacy at Risk?: A New Wave of Investigations in Europe
The AI revolution has arrived, with the recent debut of Chinese AI bot DeepSeek confirming that this is a global market. But what are the data privacy implications of the massive amounts of personal data that companies are collecting to tra
#316 Does Taking Control of Your Health Mean Losing Control of Your Data? The Privacy Risks of Healthcare Apps
Millions of us use mobile apps to help manage our physical and mental health and wellbeing. How well does existing law protect the private health data collected by these apps? In this episode, hosts Alicia Downey and Kelsey Paine talk to pr
#315 Are You In or Are You Out? Using Economics to Identify and Quantify Potential Class Members
Private class action lawsuits play a significant role in the vindication and development of U.S. antitrust law. But what are attorneys and courts to do when they know there's an injured class, but are not quite sure who's in it and who's no
#314 A New Era for Private Antitrust Litigation in China? Impact of the June 2024 Judicial Interpretation of the Supreme People’s Court
Private antitrust litigation has long been part of the landscape in China. What will be the impact of the Supreme People's Court latest judicial interpretation on the issue? Susan (Xuanfeng) Ning, lawyer at King & Wood Mallesons in Beijing,
#313 Who’s Blocking Me? Competition Law Issues With Healthcare Information Blocking
When it comes to your health, having digitized information available for seamless sharing across multiple healthcare providers and other stakeholders -- including patients themselves -- is a clear benefit. But can certain actors disrupt the
